stockrowMadrigal Pharmaceuticals, Inc.
MDGL Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.
- Revenue
- +50.1%
- EPS
- +147.3%
- Free cash flow
- +53.5%
- Total debt
- +0.45%
Quarter to September 2026, against a year earlier
Follow MDGL
Alert me
Madrigal Pharmaceuticals, Inc. (MDGL) Shares outstanding
Madrigal Pharmaceuticals, Inc.'s shares outstanding at the end of fiscal 2025 was $22.4M, up 5.46% from $21.3M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $30.3M. Over the past ten years it has ranged from $171.0K (fiscal 2015) to $22.4M (fiscal 2025) — the current reading is the highest in ten years. Madrigal Pharmaceuticals, Inc. ranks 357th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $22.4M | 5.46% |
| FY2024 | $21.3M | 13.83% |
| FY2023 | $18.7M | 9.05% |
| FY2022 | $17.1M | 3.64% |
| FY2021 | $16.5M | 7.04% |
| FY2020 | $15.4M | 0.34% |
| FY2019 | $15.4M | 4.04% |
| FY2018 | $14.8M | 20.84% |
| FY2017 | $12.2M | 135.25% |
| FY2016 | $5.2M | 2,943.86% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $30.3M | 4.01% |
| Jun 2026 | $29.1M | 0.39% |
| Mar 2026 | $29.0M | 29.41% |
| Dec 2025 | $22.4M | (21.31%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IBRX ImmunityBio, Inc. compare | $1.1B |
| CAI Caris Life Sciences,�Inc. compare | $295.1M |
| TGTX TG Therapeutics, Inc. compare | $157.3M |
| CYTK Cytokinetics, Incorporated compare | $132.1M |
| SYRE Spyre Therapeutics, Inc. compare | $88.4M |
| PTGX Protagonist Therapeutics, Inc. compare | $71.0M |
| TWST Twist Bioscience Corporation compare | $62.4M |
| KRYS Krystal Biotech, Inc. compare | $30.8M |
| MDGL Madrigal Pharmaceuticals, Inc. | $30.3M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on MDGL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- The full statement